Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaStOR study
2012-005545-20Phase 3Terminated
- Sponsor
- Institut Jules Bordet
- Start
- Oct 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised trial in gastrointestinal neuroendocrine tumor comparing 177Lu-DOTATATE arm with interferon alfa-2b arm (2 arms). Primary endpoint: Progression-free survival. Started Oct 2014; status: terminated.
02
Drugs
lutetium Lu 177 dotatateinterferon alfa-2b
03
Conditions
gastrointestinal neuroendocrine tumor
Beyond the preview
Go deeper on 2012-005545-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005545-20.